Insmed’s Promising Pipeline and Growth Potential: Buy Rating Affirmed by Analyst

Bank of America Securities analyst Jason Zemansky has maintained their bullish stance on INSM stock, giving a Buy rating on May 12.

Jason Zemansky has given his Buy rating due to a combination of factors that highlight Insmed’s promising pipeline and potential for growth. One of the key reasons is the development of TPIP, a treprostinil pro-drug currently in phase 2 trials for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Zemansky believes that even if TPIP does not achieve significant differentiation in efficacy, its improved dosing profile offers a strong commercial opportunity.
Additionally, Zemansky points to the potential of brensocatib, particularly in non-cystic fibrosis bronchiectasis, where there is a high unmet need and limited approved treatments. The management’s efforts to prepare for brensocatib’s launch could position it for substantial market success. Moreover, Insmed’s ongoing research into expanding its DPP-1 pipeline into larger inflammation and immunology indications, such as rheumatoid arthritis, further supports the Buy rating, indicating long-term growth prospects.

In another report released on May 12, Evercore ISI also reiterated a Buy rating on the stock with a $90.00 price target.